跳至主要内容
临床试验/NCT01166009
NCT01166009招募中不适用

Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Center for International Blood and Marrow Transplant Research2 个研究点 分布在 1 个国家目标入组 99,999,999 人开始时间: 2002年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
99,999,999
试验地点
2
主要终点
A Comprehensive Source of Observational Data to assess Stem Cell Transplant

研究概览

简要总结

The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.

A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.

Objectives:

To learn more about what makes stem cell transplants and cellular therapies work well such as:

  • Determine how well recipients recover from their transplants or cellular therapy;
  • Determine how recovery after a transplant or cellular therapy can be improved;
  • Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;
  • Determine how access to transplant or cellular therapy for different groups of patients can be improved;
  • Determine how well donors recover from the collection procedures.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

A Comprehensive Source of Observational Data to assess Stem Cell Transplant

时间窗: Anually - on average

A primary outcome is to have a comprehensive source of stem cell transplant data that can be used to assess topics such as: * Recipient Recover time * How recovery after transplant and other cellular therapies can be improved * Long term outcomes after transplantation and other cellular therapies * How well donors recover from collection procedure

次要结局

  • A Comprehensive Source of Data for Marrow Toxic Injuries(anually- on average)
  • Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (10CMSMDS-1)(annually - on average)
  • Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (17-CMS-SCD)(annually - on average)

研究者

申办方类型
Network
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验